Skip to content

Medical Affairs

Intelligence Hub

Overview

Home
My Work
Command Center

Plan & execute

Medical Plans
Launch Readiness
Budget & Resources
Risks & Decisions

Field & science

Engagements
Insights
Evidence Generation

Communicate

Publications
Congresses
Medical Information

Govern

Reports
Data Quality
Administration

Helixor Therapeutics

Sample data · FY2026

Scope·4 products·FY2026

HODr. Helen OkaforGlobal Head of Medical Affairs

EngagementsENG-0136

Scientific exchange · Dr. Yuki Castellano

12 Jun 2026 · In person · Dr. Yuki Castellano, Gustave Roussy · MSL Dr. Anna Becker · Nephrada

ReviewedVeeva CRMENG-0136—

Capture insight from this engagement

Location: Gustave Roussy
Therapeutic area: Nephrology
Country: France
Stakeholder tier: Tier 3
Strategic objective: Not linked
Initiative: Not linked
MSL: ABDr. Anna BeckerMSL, Nephrology (DACH)
Product: Nephrada (nephradin)

Topics discussed

Patient-reported outcomes
Proteinuria as surrogate endpoint

Scientific content used

Surrogate-endpoint evidence review
NPH mechanism-of-action deck

Questions raised

How does proteinuria reduction at 9 months translate to eGFR benefit?

Notes

Scientific exchange with academic nephrologist at Gustave Roussy. Discussed patient-reported outcomes, proteinuria as surrogate endpoint.

Insights captured (0)

Capture insight

No insights captured from this engagement.

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

Share MI standard response

0 of 1 complete

Quality ratings

1–5, rated at review

Scientific relevance: 5
Strategic relevance: 3
Depth of exchange: 5
Actionability: 3

Data lineage

Source system: Veeva CRM
Sync: Veeva CRM · synced 2026-09-15 08:00 UTC
System of record: Veeva CRM
Record id: ENG-0136

Audit history (0)

All create, update and approval events for this record

No audit events in sample data